Cybrexa Therapeutics reports favorable early Phase 1 data for its lead therapeutic candidate, CBX-12 (alphalex™-exatecan). The initial data show robust efficacy signals and tolerability in patients with metastatic cancer.
These data also serve as a key demonstration of mechanism for Cybrexa’s antigen-independent PDC tumor targeting platform, alphalex™. Cybrexa intends to investigate CBX-12 in patients with breast, ovarian and non-small cell lung cancer.